Breakthrough Device Designation
Life-threatening conditions, unmet need justification, and early evidence quality drive breakthrough designation outcomes
Key Outcomes
Early alignment with TCET and NTAP access pathways
A defensible statutory justification aligned with FDA review
Clear unmet need documentation with defined patient populations
Evidence planning that supports accelerated FDA interaction
Breakthrough Device Designation enables prioritized FDA engagement and accelerated review for technologies addressing serious or irreversibly debilitating conditions with the potential for meaningful clinical improvement. Successful designation requires clear satisfaction of FDA’s statutory framework: a well-defined unmet medical need, a reasonable expectation of improved clinical outcomes, and substantiation under at least one secondary criterion. Many MedTech companies fail to secure designation because unmet need arguments lack specificity, early evidence does not demonstrate technical or clinical feasibility, or benefit-risk justification is not clearly aligned to FDA’s statutory expectations.
UnifiMed develops structured breakthrough designation strategies that integrate unmet need definition, early evidence development, statutory criterion alignment, and downstream access planning, including TCET eligibility assessment and foundational NTAP readiness.
CHALLENGES
Where Breakthrough Designation Justifications Break Down
Across early-stage and innovative device companies, the same structural weaknesses repeatedly undermine breakthrough designation requests
Unmet need definitions lacking quantified disease burden or patient specificity
Early evidence insufficient to support meaningful improvement
Benefit–risk narratives misaligned with the selected statutory secondary criterion
Limited technical or procedural feasibility evidence for real-world use
Weak linkage between device mechanism and anticipated clinical outcomes
Claims of significant advantage without defensible comparator analysis
These gaps weaken designation justification, increase rejection risk, and delay FDA engagement that could otherwise accelerate evidence development
OUR PROCESS
How We Approach Breakthrough Device Designation
UnifiMed provides an integrated strategy that strengthens early interactions with FDA and supports a predictable regulatory pathway
Statutory Criteria Assessment and Designation Feasibility
We evaluate whether the device meets FDA’s two-part statutory framework by rigorously defining disease severity, unmet medical need, and the strongest applicable secondary criterion, based on current evidence maturity
Unmet Need Definition and Clinical Context Framing
We quantify disease burden, target population characteristics, and limitations of existing alternatives to establish a clear and defensible unmet medical need aligned with FDA expectations
Scientific Rationale and Early Evidence Integration
We integrate bench, non-clinical, and preliminary clinical evidence to demonstrate a reasonable expectation of clinically meaningful improvement, while identifying gaps that must be addressed pre- or post-designation
Benefit–Risk Narrative Development
We construct a structured benefit–risk justification that directly supports the selected statutory criterion, links device mechanism to anticipated outcomes, and accounts for known risks and mitigation controls
Designation Request and FDA Interaction Strategy
We prepare the complete breakthrough designation request and define the FDA engagement plan, including Q-Submission timing, briefing materials, and response strategy aligned with FDA’s 60-day review process
Downstream Evidence and Access Pathway Alignment
We align breakthrough designation strategy with future regulatory, coverage, and payment pathways, including TCET eligibility assessment, evidence development planning, and foundational NTAP readiness
Ready to Learn More?
Contact our team to discuss how we can support your Breakthrough Device Designation application